Literature DB >> 23163236

Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population-based study.

Shruti Garg1, Annukka Lehtonen, Susan M Huson, Richard Emsley, Dorothy Trump, D Gareth Evans, Jonathan Green.   

Abstract

AIM: To investigate psychopathology in children with neurofibromatosis type 1 (NF1), particularly the prevalence of autism spectrum disorder (ASD) and attention-deficit-hyperactivity disorder (ADHD) symptomatology, using a population-based sampling approach.
METHOD: Standard questionnaire screen reports were analysed for ASD (Social Responsiveness Scale, SRS), ADHD (Conners' Parent Rating Scale- Revised, CPRS-R), and other psychiatric morbidity (Strengths and Difficulties Questionnaire, SDQ) from parents and teachers of children aged from 4 to 16 years (112 females, 95 males) on the UK North West Regional Genetic Service register for NF1.
RESULTS: Parental response rate was 52.7% (109/207 children; 59 females, 50 males, mean age 9 y 11 mo, SD 3 y 3 mo). The SRS showed that in 29.4% (32/109) of children, autism was in the severe, clinical range (T-score>75) and in 26.6% (29/109) in the mild to moderate range (T-score 60-75). CPRS-R scores showed that in 53.8% (57/106) of children autism was in the clinical ADHD range (ADHD index T-score>65). Based on their scores on the SDQ total difficulties scale, 41.5% (44/106) of children were in the abnormal range and 14.2% (15/106) were in the borderline range. Twenty-five per cent (26/104) of children met criteria for both clinical autism and ADHD.
INTERPRETATION: This representative population-based sample of children with NF1 indicates a high prevalence of ASD symptoms associated with NF1 as well as substantial co-occurrence with ADHD symptoms. The findings clarify the psychopathology of NF1 and show the disorder as a potentially important single-gene cause for autism symptoms. © The Authors. Developmental Medicine & Child Neurology
© 2012 Mac Keith Press.

Entities:  

Mesh:

Year:  2012        PMID: 23163236     DOI: 10.1111/dmcn.12043

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  65 in total

Review 1.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

2.  RASopathies are associated with a distinct personality profile.

Authors:  Varoona Bizaoui; Jessica Gage; Rita Brar; Katherine A Rauen; Lauren A Weiss
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2018-04-16       Impact factor: 3.568

Review 3.  Sensitization of Ion Channels Contributes to Central and Peripheral Dysfunction in Neurofibromatosis Type 1.

Authors:  Aubin Moutal; Erik T Dustrude; Rajesh Khanna
Journal:  Mol Neurobiol       Date:  2016-05-11       Impact factor: 5.590

4.  Brain imaging findings and social/emotional problems in Israeli children with neurofibromatosis type 1.

Authors:  Rony Cohen; Tamar Steinberg; Liora Kornreich; Sharon Aharoni; Ayelet Halevy; Avinoam Shuper
Journal:  Eur J Pediatr       Date:  2014-07-16       Impact factor: 3.183

5.  Behavioral and cognitive outcomes for clinical trials in children with neurofibromatosis type 1.

Authors:  Thijs van der Vaart; André B Rietman; Ellen Plasschaert; Eric Legius; Ype Elgersma; Henriëtte A Moll
Journal:  Neurology       Date:  2015-10-30       Impact factor: 9.910

6.  Social Functioning and Behaviour in Mucopolysaccharidosis IH [Hurlers Syndrome].

Authors:  Annukka Lehtonen; Stewart Rust; Simon Jones; Richard Brown; Dougal Hare
Journal:  JIMD Rep       Date:  2017-07-29

7.  Social Function and Autism Spectrum Disorder in Children and Adults with Neurofibromatosis Type 1: a Systematic Review and Meta-Analysis.

Authors:  Anita K Chisholm; Vicki A Anderson; Natalie A Pride; Stephanie Malarbi; Kathryn N North; Jonathan M Payne
Journal:  Neuropsychol Rev       Date:  2018-08-11       Impact factor: 7.444

8.  Neurofibromatosis Type 1 Implicates Ras Pathways in the Genetic Architecture of Neurodevelopmental Disorders.

Authors:  Jessica A Kaczorowski; Taylor F Smith; Amanda M Shrewsbury; Leah R Thomas; Valerie S Knopik; Maria T Acosta
Journal:  Behav Genet       Date:  2020-02-05       Impact factor: 2.805

9.  Distribution and Within-Family Specificity of Quantitative Autistic Traits in Patients with Neurofibromatosis Type I.

Authors:  John N Constantino; Yi Zhang; Kieran Holzhauer; Sayli Sant; Kyna Long; Alicia Vallorani; Leena Malik; David H Gutmann
Journal:  J Pediatr       Date:  2015-06-04       Impact factor: 4.406

10.  Brief Report: The Prevalence of Neurofibromatosis Type 1 among Children with Autism Spectrum Disorder Identified by the Autism and Developmental Disabilities Monitoring Network.

Authors:  Deborah A Bilder; Amanda V Bakian; David A Stevenson; Paul S Carbone; Christopher Cunniff; Alyson B Goodman; William M McMahon; Nicole P Fisher; David Viskochil
Journal:  J Autism Dev Disord       Date:  2016-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.